| Project/Area Number |
17390260
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Metabolomics
|
|---|
| Research Institution | Yokohama City University |
|---|
Principal Investigator |
TERAUCHI Yasuo Yokohama City University, Department of Endocrinology and Mptahnlisrn, Prnfessor, 医学研究科, 教授 (40359609)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
YAMAUCHI Toshimasa The University of Tbkyo, Department of Metabolic Diseases, Associate Professor, 医学部附属病院, 寄附講座教員(客員助教授) (40372370)
KADOWAKI Takashi The University of Tokyo, Department of Metabolic Diseases, Professor, 医学部附属病院, 教授 (30185889)
TOBE Kazuyuki The University of Tokyo, Department of Metabolic Diseases, Associate Professor, 医学部附属病院, 講師 (30251242)
|
|---|
| Project Period (FY) |
2005 – 2006
|
| Project Status |
Completed (Fiscal Year 2006)
|
| Budget Amount *help |
¥15,400,000 (Direct Cost: ¥15,400,000)
Fiscal Year 2006: ¥5,900,000 (Direct Cost: ¥5,900,000)
Fiscal Year 2005: ¥9,500,000 (Direct Cost: ¥9,500,000)
|
|---|
| Keywords | diabetes / gene / signal transduction / PPAR / adiponectin / insulin / obesity / fat cell |
|---|
| Research Abstract |
We investigated the role of resistin in obesity-linked insulin resistance and central nervous system. Up-regulation of adiponectin by thiazolidinedione has been proposed to be a major mechanism of the thiazolidinedione-induced amelioration of insulin resistance linked to obesity. To test this hypothesis, we generated adiponectin knock-out (adipo-/-) ob/ob mice with a C57B/6 background. After 14 days of 10 mg/kg pioglitazone, the insulin resistance and diabetes of ob/ob mice were significantly improved in association with significant up-regulation of serum adiponectin levels. In contrast, insulin resistance and diabetes were not improved in adipo-/-ob/ob mice. After 14 days of 30 mg/kg pioglitazone, insulin resistance and diabetes of ob/ob mice were again significantly ameliorated. Interestingly, adipo-/-ob/ob mice also displayed significant amelioration of insulin resistance and diabetes. The serum-free fatty acid and triglyceride levels as well as adipocyte sizes in ob/ob and adipo-/-
… More
ob/ob mice were unchanged after 10 mg/kg pioglitazone but were significantly reduced to a similar degree after 30 mg/kg pioglitazone. Moreover, the expressions of TNFalpha and resistin in adipose tissues of ob/ob and adipo-/-ob/ob mice were unchanged after 10 mg/kg pioglitazone but were decreased after 30 mg/kg pioglitazone. Thus, pioglitazone-induced amelioration of insulin resistance and diabetes may occur via adiponectin-dependent and and-independent pathways.
Adiponectin plays a central role as an antidiabetic and antiatherogenic adipokine. AdipoRl and AdipoR2 serve as receptors for adiponectin in vitro, and their reduction in obesity seems to be correlated with reduced adiponectin sensitivity. Adenovirus-mediated expression of AdipoRl and R2 in the liver of Lepr(-/-) mice increased AMP-activated protein kinase (AMPK) activation and peroxisome proliferator-activated receptor (PPAR)-alpha signaling pathways, respectively. Activation of AMPK reduced gluconeogenesis, whereas expression of the receptors in both cases increased fatty acid oxidation and lead to an amelioration of diabetes. Alternatively, targeted disruption of AdipoRl resulted in the abrogation of adiponectin-induced AMPK activation, whereas that of AdipoR2 resulted in decreased activity of PPAR-alpha signaling pathways. Thus, AdipoRl and R2 serve as the predominant receptors for adiponectin in vivo and play important roles in the regulation of glucose and lipid metabolism, inflammation and oxidative stress in vivo.
We are also investigating the structure and role of resistin in central nervous system. Less
|
